Get research updatesAnxiety conditions involve intense, persistent fears or worries that can interfere with everyday life.
This study has finished and is no longer accepting participants.
Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.
In Czech RepublicThis study has finished and is no longer accepting participants.
Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.
In GermanyThis study has finished and is no longer accepting participants.
Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.
In FinlandThis study has finished and is no longer accepting participants.
Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.
In FinlandCurrent recruitment status is unconfirmed.
This older record does not confirm current recruitment. No matching public CTIS record was confirmed using this identifier. Ask the research team for an up-to-date source.
In United Kingdom
This study isn't currently recruiting.
In Germany
This study isn't currently recruiting.
In Australia
This study isn't currently recruiting.
In GermanyResearchers compared SEP-363856 and placebo to find out how the approaches affected anxiety symptoms in adults with an anxiety condition.
This study has finished and is no longer accepting participants.
Multiple locations, including HuntsvilleResearchers compared 225 mg BNC210, 675 mg BNC210 and placebo, tracking side effects to assess safety in people with an anxiety condition.
This study has finished and is no longer accepting participants.
Multiple locations, including Beverly HillsBVR-100 and BES-100 Validation Trial: A Randomized, Double-Blind, Parallel-Group, Controlled Study of Two At-Home Self-Guided Virtual Reality Interventions for Adults With Social Anxiety Disorder.
This study has finished and is no longer accepting participants.
Multiple locations, including OrlandoA Multicenter, Randomized, Double-blind, Placebo-controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets in Participants With Generalized Anxiety Disorder.
This study has finished and is no longer accepting participants.
In BeijingWe gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.